Sermorelin vs Ipamorelin
They act on two different receptors, which is why the people who research this question carefully usually stop treating it as a question. The bigger difference between them is not pharmacological at all.
This guide compares two growth hormone secretagogues on mechanism, human evidence, regulatory standing and practical use. It is educational only and not a substitute for advice from a qualified healthcare professional. Sources are listed at the end.
Both compounds do the same broad thing: they prompt your pituitary to release its own growth hormone, rather than supplying growth hormone from outside. Both preserve the feedback loop that stops the body overshooting. Both are injected, both are used in the evening, and both are sold side by side.
They get there through completely different receptors, and almost every practical difference between them follows from that one fact.
The Quick Answer
If you read nothing else
Sermorelin is a fragment of your own growth hormone-releasing hormone. It was an approved medicine, its approval was withdrawn for business reasons rather than safety, and that history gives it a legitimate pharmacy pathway that ipamorelin does not have. Ipamorelin works through the ghrelin receptor instead, and its genuine advantage is selectivity — it raises growth hormone without dragging cortisol and prolactin up with it, which the older compounds in its class did. They are complementary rather than competing, and the standard research approach combines a GHRH analogue with a GHRP precisely because the two pathways amplify each other. Neither has trial evidence for the adult body-composition and anti-aging uses they are actually sold for.
Two Receptors, Not Two Rivals
Your pituitary releases growth hormone in pulses, and it takes instructions from more than one source. Two of those inputs matter here.
Sermorelin is GHRH(1-29) — the first 29 amino acids of growth hormone-releasing hormone, which is the active portion of the natural 44-residue hormone. It binds the GHRH receptor. In effect it is the body's own "release growth hormone" signal, trimmed to its working part.
Ipamorelin is a five-amino-acid molecule that binds GHS-R1a — the ghrelin receptor. Ghrelin is best known as a hunger hormone, but the same receptor also triggers growth hormone release, and this is a separate door into the same room.
Simplified. The pulse pattern, not just the total, is what distinguishes secretagogues from exogenous growth hormone.
For the wider picture of how this axis works and what else acts on it, see how growth hormone peptides work and peptides versus HGH.
Head to Head
| Sermorelin | Ipamorelin | |
|---|---|---|
| What it is | 29-amino-acid fragment of natural GHRH | Synthetic five-amino-acid molecule |
| Receptor | GHRH receptor | GHS-R1a, the ghrelin receptor |
| Half-life | Minutes — commonly reported in the region of 10 to 20 | About 2 hours |
| Regulatory history | FDA approved 1990 and 1997; withdrawn 2008–09 for business reasons | Never approved anywhere; one phase 2 programme discontinued |
| Compounding pathway | Yes, as a component of a previously approved product | No — advisory committee voted against inclusion |
| Hormonal selectivity | Acts upstream on its own pathway; not characterised for selectivity the way ipamorelin is | Well characterised — no meaningful rise in cortisol, prolactin or ACTH |
| Appetite effect | None described | Minimal, unlike GHRP-6 in the same class |
| Anti-doping | Prohibited at all times, WADA S2 | Prohibited at all times, WADA S2 |
Selectivity — ipamorelin's real advantage
This is the claim most worth taking seriously, because it is properly documented. Ipamorelin was characterised in 1998 as the first growth hormone-releasing peptide to stimulate GH release with what its developers called absolute selectivity: no significant elevation of cortisol, ACTH, prolactin, FSH or LH at pharmacological doses.
That distinguished it from its predecessors. GHRP-6 produces intense hunger through broader ghrelin-receptor activation; GHRP-2 can raise cortisol and prolactin at higher doses. Both effects complicate long-term use. Ipamorelin was engineered specifically to avoid them, and by the evidence available it succeeded.
Sermorelin is often described as equally "clean," which is fair in the sense that no comparable problems have been reported — but it has not been through the same selectivity characterisation, so the two claims are not equally supported.
What the Human Evidence Shows
Here the asymmetry runs the other way, and it is larger than most comparisons acknowledge.
Sermorelin
Sermorelin has genuine clinical trial history. It was approved in 1990 as Geref Diagnostic for assessing pituitary function, and again in 1997 under NDA 20-443 for treating idiopathic growth hormone deficiency in children with growth failure. The sermorelin stimulation test was a recognised diagnostic procedure — a single intravenous dose followed by serial GH measurements — used as an alternative to the insulin tolerance test.
That is real evidence, in real patients, reviewed by a regulator. The catch is the population: children with diagnosed growth hormone deficiency. It says very little about a metabolically healthy adult in their forties.
Ipamorelin
Ipamorelin was developed by Novo Nordisk in the late 1990s and characterised in a well-regarded pharmacology paper. It then went into phase 2 trials with Helsinn Therapeutics for postoperative ileus — the slowdown of gut motility that follows abdominal surgery, chosen because ghrelin-receptor agonists affect gut motility.
That programme was discontinued for lack of efficacy. It is the only phase 2 human programme ipamorelin has had, and it did not work for the thing it was tested on.
What neither of them has
Neither compound has a controlled trial supporting the uses they are actually marketed for in adults — body composition, recovery, sleep quality, skin, or anything described as anti-aging. Sermorelin's evidence is paediatric growth failure. Ipamorelin's is a failed gut-motility trial. Everything said about adult wellness outcomes is extrapolation from the growth hormone axis in general, not from studies of these compounds for those purposes.
The Difference Nobody Leads With
Comparisons of these two almost always turn on receptors and half-lives. The difference that actually determines what you can legitimately obtain, and from whom, is legal — and it is the section most pages skip.
Sermorelin: a pathway exists
Geref was discontinued by EMD Serono in December 2008 and the approvals withdrawn in 2009. Crucially, a Federal Register determination confirmed the withdrawal was not for reasons of safety or effectiveness — it was a commercial decision, as the paediatric market moved toward recombinant growth hormone.
That distinction is not trivia. US compounding law requires a bulk substance to satisfy one of three conditions, and one of them is being a component of an FDA-approved drug product. Because Geref was approved and was not pulled for safety, sermorelin clears that bar. It is why compounding pharmacies can legally prepare sermorelin today.
Ipamorelin: no pathway, and a correction
Ipamorelin's position is more complicated, and a lot of current writing on it is out of date. The sequence:
- September 2023 — ipamorelin acetate placed in Category 2 of the FDA's interim 503A bulks list, meaning compounding pharmacies could not use it.
- September 2024 — following litigation brought by compounding-sector companies, ipamorelin was removed from Category 2 after the original nominator withdrew the nomination, alongside AOD-9604, CJC-1295, thymosin alpha-1 and Selank.
- October 2024 — the Pharmacy Compounding Advisory Committee reviewed ipamorelin for inclusion on the 503A Bulks List and voted against it, along with ibutamoren and kisspeptin-10.
Regulatory positions move. Verify current status before relying on any of this.
The practical result: ipamorelin is no longer on a "do not compound" list, but it is not eligible for compounding either. It sits in between. Anything sold as ipamorelin comes through research-compound channels, which makes the sourcing questions in our guide to purity and certificates of analysis matter more for it than for sermorelin.
You will still find pages published in 2026 stating flatly that ipamorelin is Category 2. That has not been true since September 2024.
Using Them Together
This is where the "versus" framing breaks down. Because GHRH analogues and GHRPs act on separate receptor systems, combining them produces a growth hormone pulse larger than adding the two effects together — the standard description is synergistic rather than additive. It is why the most common research pairing is a GHRH analogue plus a GHRP taken at the same time, rather than either alone.
One caveat that gets dropped
The synergy finding is a property of the two receptor classes, and the studies establishing it generally used GHRH together with GHRP-2 rather than sermorelin together with ipamorelin specifically. The mechanism gives good reason to expect the same behaviour from this pairing, but "expected from mechanism" and "demonstrated in a trial" are different claims, and the second one has not been made for this combination. Combining also means combining unknowns: no interaction or long-term safety data exists for either compound in adult non-deficient use, let alone for both together. See peptide drug interactions.
The same logic explains why ipamorelin is more often paired with CJC-1295 than with sermorelin in practice — CJC-1295 is a modified GHRH analogue with a longer duration, which fits ipamorelin's two-hour window better than sermorelin's few minutes.
Dosing in the Research
No adult dose of either compound has been validated for the purposes they are marketed for. What exists is one paediatric label and a body of convention.
| Source | Compound | Dose reported | Notes |
|---|---|---|---|
| Geref prescribing information | Sermorelin | 0.03 mg/kg/day | Children with growth hormone deficiency — roughly 2 mg/day scaled to a 70 kg adult |
| Pharmacology studies | Ipamorelin | Varies by study design | Characterisation work in animals and early human pharmacology, not efficacy trials |
| Community convention | Both | Hundreds of micrograms, at night | Not derived from any published adult trial for these purposes |
Note the gap on the sermorelin line: the only approved-label dose is roughly an order of magnitude above what circulates in adult protocols, and it was for a different population with a different indication. That does not make the smaller figure wrong — it makes it unstudied.
Timing convention differs for a reason that does make sense. Sermorelin clears in minutes, so it is dosed at night to land alongside the body's largest natural pulse during deep sleep. Ipamorelin's two-hour window is more forgiving. If you are running either, our guide on tracking your progress covers what to measure — IGF-1 is the practical marker, since growth hormone itself pulses too much to test usefully.
Safety & Anti-Doping
Both share the class effects of raising growth hormone: fluid retention, joint aches, tingling or numbness in the hands, and reduced insulin sensitivity with rising blood glucose. That last one is the effect worth monitoring rather than feeling for, and it is why baseline bloodwork matters more here than with most compounds.
Injection-site reactions are common to both. Ipamorelin's selectivity means it avoids the cortisol and prolactin elevation seen with older GHRPs, which is a real advantage over its own class but not over sermorelin.
Where caution applies to both
Diabetes or impaired glucose tolerance. Reduced insulin sensitivity is the documented class effect. Anyone on glucose-lowering medication should involve their prescriber. Active or prior cancer. The growth hormone axis and IGF-1 intersect with cell proliferation, and this is a conversation for an oncologist rather than a supplier. Pregnancy and breastfeeding. No data. Competitive athletes. Both compounds are prohibited at all times under WADA's S2 category covering peptide hormones, growth factors and their mimetics — in and out of competition. Growth hormone secretagogues are explicitly within scope, and detection methods exist. Confirm with your national anti-doping organisation.
Which Should You Be Asking About
A more useful framing than picking a winner.
If regulatory standing matters to you
Sermorelin, without much argument. It is the only one of the two with a legitimate pharmacy route, which also means a supervised route with bloodwork attached.
If you want the best-characterised safety profile in its class
Ipamorelin. The selectivity data is genuinely good, and it is the reason ipamorelin displaced GHRP-6 and GHRP-2 in practice.
If you are combining anyway
Then the question was never either-or. Most protocols pair a GHRH analogue with a GHRP, and the pairing is the point.
If you have not had bloodwork
Neither, yet. IGF-1, fasting glucose and a basic panel first. Without a baseline you cannot tell whether anything happened.
And the honest structural point: for adults without diagnosed growth hormone deficiency, the strongest lever on natural growth hormone output is not either compound. It is sleep — the largest natural pulse of the day occurs during slow-wave sleep — followed by resistance training. Both are free, both have better evidence than anything on this page, and neither is prohibited in sport.
Common Questions
Which one produces more growth hormone?
In head-to-head terms the question is not well answered, because the comparison depends heavily on dose, timing and whether the pituitary's own pulse rhythm is being worked with or against. What is established is that combining the two receptor pathways produces more than either alone — which is a better answer than picking one.
Is sermorelin safer because it was FDA approved?
It has more regulatory scrutiny behind it, which is meaningful. But the approval was for children with growth hormone deficiency at a specific dose, and it was withdrawn in 2009. Neither compound has been evaluated by a regulator for adult wellness use, so "approved" should not be read across to the way it is used now.
Does ipamorelin make you hungry?
Far less than GHRP-6, which is one of the main reasons it replaced it. Because it acts on the ghrelin receptor some appetite effect is mechanistically plausible, and it is occasionally reported, but the intense hunger associated with the older compounds is not a characteristic of ipamorelin.
Why does sermorelin have such a short half-life?
Because it is essentially the natural hormone, and the natural hormone is meant to be a brief signal. GHRH is degraded quickly by design — the body's pulse system depends on the signal switching off. Longer-acting versions like CJC-1295 exist precisely because chemists modified the molecule to resist that degradation.
Can I get either through a doctor?
Sermorelin, in principle, through a compounding pharmacy in jurisdictions where that route exists — that is exactly what its regulatory history enables. Ipamorelin has no such pathway following the 2024 advisory vote. In Costa Rica both are sold as research compounds; see our FAQ page.
How long before anything shows up?
IGF-1 is the marker, and it can move within about four to six weeks. Body-composition endpoints take considerably longer — eight to twelve weeks at minimum, often more. Anyone reporting dramatic changes in week one is describing expectation rather than the growth hormone axis, which does not work that fast.
What about tesamorelin?
Tesamorelin is the one GHRH analogue with a current FDA approval, for reducing excess visceral fat in HIV-associated lipodystrophy. If regulatory standing and trial evidence are what you care about, it has more of both than either compound here — though for a specific indication. See our tesamorelin guide.
Should I cycle them?
Cycling schedules for these compounds come from convention rather than from studies of receptor desensitisation to them specifically. The mechanistic concern with ghrelin-receptor agonists is more plausible than with GHRH analogues, but neither has the data to support a particular schedule.
What does Peptides Costa Rica carry?
Both, plus CJC-1295 and tesamorelin. Current vial sizes, pricing and stock are on each product page, and five or more vials of the same product carry an automatic 15% discount. Our full guides on sermorelin and ipamorelin cover each in depth.
Still not sure which fits?
Tell us what you're actually trying to change and we'll give you a straight read — including when the answer is bloodwork first, or that neither is the right tool for the goal.
Contact Us on WhatsAppImportant disclaimer: The information in this guide is general educational content only. It is not medical advice, a prescription, or a personalized recommendation. Sermorelin held FDA approval as Geref for the diagnosis and treatment of growth hormone deficiency in children; that approval was withdrawn in 2009 following the manufacturer's discontinuation of the product, which a Federal Register determination confirmed was not for reasons of safety or effectiveness. Ipamorelin has never been approved by any regulatory authority; its only phase 2 human programme, in postoperative ileus, was discontinued for lack of efficacy. Neither compound is approved by the FDA, the EMA, or Costa Rica's Ministerio de Salud for adult use relating to body composition, recovery, sleep, skin or aging, and neither has controlled trial evidence supporting those uses; both are sold here as research compounds intended for laboratory and scientific study. Regulatory positions described reflect the record at the time of writing and change frequently; verify current status before relying on it. Dosing figures discussed reflect an approved paediatric label and reported community use; they are not endorsements of those doses for any individual, and no adult dose has been validated for these purposes. Growth hormone secretagogues are associated with fluid retention, joint pain, carpal tunnel symptoms and reduced insulin sensitivity with elevated blood glucose. No interaction studies exist for either compound, and no safety data exists for long-term adult use, pregnancy or breastfeeding. The synergy described between GHRH analogues and growth hormone-releasing peptides is established for the receptor classes generally and has not been demonstrated in a trial of this specific pairing. Both compounds are prohibited at all times, in and out of competition, under the World Anti-Doping Agency's S2 category covering peptide hormones, growth factors and mimetics. Always consult a qualified healthcare professional before beginning any peptide protocol. Products sold by Peptides Costa Rica are intended for laboratory and research purposes only.
- European Journal of Endocrinology (Raun et al., 1998): Characterisation of ipamorelin as the first growth hormone-releasing peptide to stimulate GH release with selectivity, without significant elevation of cortisol, ACTH, prolactin, FSH or LH.
- US Federal Register determination, Docket FDA-2012-P-1071: Geref (sermorelin acetate) injection, NDA 20-443 held by EMD Serono and approved 26 September 1997, was withdrawn from sale in December 2008 for business reasons and not for reasons of safety or effectiveness.
- FDA prescribing information for Geref: Approved paediatric dosing of 0.03 mg/kg/day for idiopathic growth hormone deficiency, and the sermorelin stimulation test as a pituitary function assessment.
- Adis and pharmacology literature (Beck & Sweeney, 2014): Ipamorelin developed by Novo Nordisk, investigated in phase 2 by Helsinn Therapeutics for postoperative ileus, and discontinued due to lack of efficacy.
- FDA interim 503A bulk drug substances list and associated notices: Ipamorelin acetate placed in Category 2 in September 2023 and removed effective 27 September 2024 following withdrawal of the nomination, alongside AOD-9604, CJC-1295, thymosin alpha-1 and Selank acetate.
- Alliance for Pharmacy Compounding reporting on the Pharmacy Compounding Advisory Committee, October 2024: The committee voted against adding ipamorelin, ibutamoren mesylate, kisspeptin-10 and L-theanine to the 503A bulks list.
- FDA Pharmacy Compounding Advisory Committee briefing materials (October 2024): Agency evaluation of ipamorelin-related bulk drug substances, including characterisation and the postoperative ileus literature cited by the nominator.
- Growth hormone secretagogue pharmacology literature: Synergistic growth hormone release when GHRH analogues are combined with growth hormone-releasing peptides acting at GHS-R1a, and the class effects of GH elevation including reduced insulin sensitivity.
- World Anti-Doping Agency: Prohibited List, section S2, covering peptide hormones, growth factors, related substances and mimetics, including growth hormone secretagogues, prohibited at all times.
